Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley rats

Abstract

Background:

Levamisole (LVM) is a common adulterant in clandestinely manufactured cocaine (COC), with a range of well-documented deleterious health effects. Although the prevalence of LVM in COC has been widely noted, the subjective effects related to concomitant COC-LVM administration are poorly understood.

Aims:

The present study sought to compare the subjective effects of LVM alone and in combination with COC in male and female Sprague-Dawley rats trained to discriminate COC from vehicle injections.

Methods:

Male and female Sprague-Dawley rats were trained to discriminate COC from vehicle injections using a two-lever, food-reinforced drug discrimination procedure. Subsequent dose-effect curves were generated for COC, LVM, and a variety of COC-LVM combinations.

Results:

No significant difference in males and females was observed on any measure of responding. LVM alone dose-dependently decreased response rates and failed to produce substitution for COC. When LVM was administered with COC, previously ineffective doses of COC engendered COC-appropriate responding.

Conclusions:

LVM potentiates the subjective effects of COC when administered concomitantly. These findings are consistent with the popular notion that LVM is added as an adulterant to COC to amplify the subjective effects of COC administration.

Keywords

Cocaine levamisole adulterant subjective effects rat

Get full access to this article

View all access options for this article.

References

Adams

(1978) Pharmacokinetics of levamisole. J Rheumatol Suppl 4: 137–142.

Bauman

DiDomenico

(2002) Cocaine-induced channelopathies: Emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Ther 7: 195–202.

Bertol

Mari

Milia

et al . (2011) Determination of aminorex in human urine samples by GC-MS after use of levamisole. J Pharm Biomed Anal 55: 1186–1189.

Boggiano

Cavigelli

Dorsey

et al . (2008) Effect of a cage divider permitting social stimuli on stress and food intake in rats. Physiol Behav 95: 222–228.

Carroll

Anker

(2010) Sex differences and ovarian hormones in animal models of drug dependence. Horm Behav 58: 44–56.

Casale

Corbeil

Hays

(2008) Identification of levamisole impurities found in illicit cocaine exhibits. Microgram J 6: 82–89.

Chiadmi

Lyer

Cisternino

et al . (2005) Stability of levamisole oral solutions prepared from tablets and powder. J Pharm Sci 8: 322–325.

Chitwood

(1985) Patterns and consequences of cocaine use. In: Kozel

Adams

(eds) Cocaine use in America: Epidemiologic and clinical perspectives. Rockville, MD: US Department of Health and Human Services, pp. 111–129.

Colpaert

Niemegeers

CJE

Janssen

PAJ

(1978) Factors regulating drug cue sensitivity. A long-term study on the cocaine cue. In: Colpaert

Rosecrans

(eds) Stimulus Properties of Drugs: Ten Years of Progress. Amsterdam: Elsevier/North-Holland Biomedical Press, pp. 281–299.

10.

Convention on Psychotropic Substances (1971) Convention on Psychotropic Substances. Available at: https://www.unodc.org/pdf/convention_1971_en.pdf (accessed 16 May 2018).

11.

Craft

Kalivas

Stratmann

(1996) Sex differences in discriminative stimulus effects of morphine in the rat. Behav Pharmacol 7: 764–778.

12.

Craft

Stratmann

(1996) Discriminative stimulus effects of cocaine in female versus male rats. Drug Alcohol Depend 42: 27–37.

13.

de La Garza

Johanson

(1987) Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys. J Pharmacol Exp Ther 243: 955–962.

14.

Dren

Jochimsen

Plotnikoff

(1971) Comparison of pemoline, cocaine, methamphetamine and methylphenidate self-administration in monkeys. Pharmacologist 13: 281.

15.

Drug Enforcement Administration (2013) Levamisole (Ergamisol^®). Drug and Chemical Evaluation Section. https://www.deadiversion.usdoj.gov/drug_chem_info/levamisole.pdf (accessed 16 May 2018).

16.

Engelmann

Richardson

(1986) Effects of levamisole on primary cultures of adult rat hepatocytes. Biochem Pharmacol 9: 1547–1554.

17.

FDA (2017) Assessment of Abuse Potential of Drugs: Guidance for Industry. Available at: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm198650.pdf (accessed 16 May 2018).

18.

Fischman

Foltin

(1991) Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86: 1563–1570.

19.

Galtier

Coche

Alvinerie

(1983) Tissue distribution and elimination of [3H]levamisole in the rat after oral and intramuscular administration. Xenobiotica 13: 407–413.

20.

Gauvin

Baird

(1999) Discriminative effects of compound drug stimuli: A focus on attention. Pharmacol Biochem Behav 64: 229–235.

21.

Gauvin

Briscoe

Baird

et al . (1996) Selective attention to elements of a morphine stimulus: Idiosyncratic stimulus additivity of incidental cues. Exp Clin Psychopharmac 4: 379–388.

22.

Gauvin

Zimmermann

(2017) Conducting preclinical abuse liability screening in only one sex: Making a case for “reasonable exclusion.” Pharm Regul Aff 6: 1–16.

23.

Glennon

Young

(2011) Drug discrimination: Practical considerations. In: Glennon

Young

(eds) Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. Hoboken, NJ: John Wiley & Sons, Inc., pp. 41–128.

24.

Hess

Ritke

Broecker

et al . (2014) Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS. Anal Bioanal Chem 405: 4077–4088.

25.

Hofmaier

Luf

Seddik

et al . (2014) Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. Neurochem Int 73: 32–41.

26.

Jiménez-González

Ros-Moreno

Moreno-Guzmán

et al . (1999) Characterization of levamisole binding sites Trichinella spiralis. Parasitol Res 84: 747–759.

27.

KDIGO (2012) Chapter 3: Steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl (2011) 2: 163–171.

28.

Kouassi

Caillé

Léry

et al . (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm Drug Dispos 7: 71–89.

29.

Levandoski

Piket

Chang

(2003) The anthelmintic levamisole is an allosteric modulator of human neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 471: 9–20.

30.

Luyckx

Rousseau

Cazin

et al . (1982) Pharmacokinetics of levamisole in healthy subjects and cancer patients. Eur J Drug Metab Pharmacokinet 7: 247–254.

31.

Martin

Robertson

(2010) Control of nematode parasites with agents acting on neuro musculature systems: Lessons for neuropeptide ligand discovery. Adv Exp Med Biol 692: 138–154.

32.

McCullough

de Vries

Miller

et al . (2014) NIH initiative to balance sex of animals in preclinical studies: Generative questions to guide policy, implementation, and metrics. Biol Sex Differ 5: 15.

33.

Murray

Al-Shoura

(1976) Stability of cocaine hydrochloride in aqueous solution [proceedings]. J Pharm Pharmacol 28 (Suppl): 24P.

34.

Mutch

Hutson

(1991) Levamisole in the adjuvant treatment of colon cancer. Clin Pharm 10: 95–109.

35.

National Research Council (2011) Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press.

36.

Negus

Banks

(2011) Making the right choice: Lessons from drug discrimination for research on drug reinforcement and drug self-administration. In: Glennon

Young

(eds) Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. Hoboken, NJ: John Wiley & Sons, Inc., pp. 361–388.

37.

Nowak

Rosay

Czégé

et al . (2015) Tetramisole and levamisole suppress neuronal activity independently from their inhibitory action on tissue non-specific alkaline phosphatase in mouse cortex. Subcell Biochem 76: 239–281.

38.

Onuaguluchi

Igbo

INA

(1990) Electrocardiographic changes induced by levamisole hydrochloride in the rat. Arch Int Pharmacodyn Ther 305: 55–62.

39.

Robertson

Bjorn

Martin

(1999) Resistance to levamisole resolved at the single channel level. FASEB J 13: 749–760.

40.

Single Convention on Narcotic Drugs (1961) As Amended by the 1972 Protocol Amending the Single Convention on Narcotic Drugs. Available at: https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf (accessed 16 May 2018).

41.

Spector

Munjal

Schmidt

(1998) Effects of the immunostimulant, levamisole, on opiate withdrawal and levels of endogenous opiate alkaloids and monoamine neurotransmitters in rat brain. Neuropsychopharmacology 19: 417–427.

42.

Stadler

Caul

Barrett

(2001) Effects of training dose on amphetamine drug discrimination: Dose-response functions and generalization to cocaine. Pharmacol Biochem Behav 70: 381–386.

43.

Stolerman

Childs

Ford

et al . (2011) Role of training dose in drug discrimination: A review. Behav Pharmacol 22: 15–29.

44.

Symoens

Veys

Mielants

et al . (1978) Adverse reactions to levamisole. Cancer Treat Rep 62: 1721–1730.

45.

Tallarida

Egan

Alejo

et al . (2014) Levamisole and cocaine synergism: A prevalent adulterant enhances cocaine’s action in vivo. Neuropharmacology 79: 590–595.

46.

Tallarida

Rawls

(2015) Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats. Drug Alcohol Depend 149: 145–150.

47.

Tallarida

(2000) Drug Synergism and Dose-Effect Data Analysis. Boca Raton, FL: Chapman & Hall/CRC.

48.

Tallarida

Murray

(1987) Manual of Pharmacologic Calculations with Computer Programs. 2nd ed. New York: Springer-Verlag.

49.

United Nations (1988) United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Available at: http://www.unodc.org/pdf/convention_1988_en.pdf (accessed 16 May 2018).

50.

United States Department of Justice (2002) Federal Cocaine Offenses: An Analysis of Crack and Powder Penalties. Available at: https://www.justice.gov/archive/olp/pdf/crack_powder2002.pdf (accessed 16 May 2018).

51.

Wilson

Hitomi

Schuster

(1969) Further studies of the self-administration of psychomotor stimulants in the rhesus monkey. In: Committee on Problems of Drug Dependence: Report of the Thirty-first meeting. Washington, DC: National Academy of Sciences – National Research Council, pp. 6057–6063.

52.

Woolverton

(2014) Analysis of drug interactions in behavioral pharmacology. In: Thompson

Dews

Barrett

(eds) Advances in Behavioral Pharmacology: Volume 6: Neurobehavioral Pharmacology. New York: Psychology Press, pp. 275–302.

53.

Woolverton

Massey

Winger

et al . (1994) Evaluation of the abuse liability of aminorex. Drug Alcohol Depend 36: 187–192.

54.

Woolverton

Wang

Vasterling

et al . (2008) Self-administration of drug mixtures by monkeys: Combining drugs with comparable mechanisms of action. Psychopharmacology (Berl) 196: 575–582.

55.

Young

Glennon

(1993) Cocaine-stimulus generalization to two new designer drugs: Methcathinone and 4-methylaminorex. Pharmacol Biochem Behav 45: 229–231.

56.

Zimmermann

Gauvin

Poling

(2017) Effects of levamisole on cocaine self- administration by rats. Psychol Rec 67: 559–567.